Individualization of Radionuclide Therapies: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Hanna Piwowarska-Bilska
,
Sara Kurkowska
,
Bożena Birkenfeld
,
Hanna Piwowarska-Bilska

Evidence shows that better and more predictable outcomes can be achieved with patient-individualized dose assessment. Therefore, the incorporation of individual planning into radionuclide therapies is a high priority for nuclear medicine physicians and medical physicists alike. Internal dosimetry is used in tumor therapy to optimize the absorbed dose to the target tissue.  For a nuclear medicine therapy to be considered personalized, treatment planning is essential, including the activity chosen individually for a given patient. The first step in individual planning of radioisotope therapy is to perform a series of diagnostic images, which allows visualizing the distribution and measuring how the activity decreased in time in different organs. The next step is to perform dosimetric measurements. It provides information on the degree of uptake of an administered radiopharmaceutical in pathological tissues and critical organs. The obtained dosimetric report is the foundation for planning the maximum activity on tumors, with a safe level of irradiation of critical organs in a given patient. The last step is to obtain a series of images of the patient recorded after the administration of the therapeutic radiopharmaceutical. 

  • internal dosimetry
  • radiopharmaceuticals
  • radionuclide therapy

1. Introduction

Nuclear medicine uses radiopharmaceuticals, which are various molecules labeled with radioactive isotopes, for diagnosis and therapy. Radiopharmaceuticals are sources of radiation, and when introduced into the patient’s body (by injection, oral administration, or inhalation), they target specific organs, tissues, or cells. Subsequently, the activity of radiopharmaceuticals in tissues decreases due to their elimination from the body and radioactive decay. Administration of the same activity of a given radiopharmaceutical to different patients can distribute in their bodies differently, and therefore it is important to consider each patient individually. The determination of the total number of nuclear disintegrations that occur in a particular organ allows calculating the mean energy absorbed per kilogram of tissue. This parameter is known as the mean absorbed dose.
The knowledge of the absorbed ionizing radiation dose after administration of a radioactive preparation is of great importance both for the patient’s safety and for the proper course of diagnostics or radioisotope therapy. The activity of radioisotopes, administered to patients for diagnostic imaging studies, must ensure the correct image quality while minimizing the dose that will be absorbed. Due to the increase in sensitivity of modern gamma cameras, the reported diagnostic activities are low. However, in the case of radioisotope therapy, the activity of the therapeutic radioisotope should be as high as possible to effectively destroy tumor cells, and at the same time, low enough not to damage critical organs. Therapy using radioactive isotopes is an extremely important and rapidly developing part of nuclear medicine. Modern radioisotope treatments are based on the idea of theranostics [1][2], according to which a diagnostic examination should be performed with the use of a radiopharmaceutical with the same distribution as the therapeutic radiopharmaceutical. Only when the result of the primary examination shows a sufficiently high accumulation of diagnostic radiopharmaceutical is the patient eligible for the treatment procedure.
In every clinical situation that requires the administration of a radioactive substance to the patient, it is important to know the absorbed dose. Moreover, it is of special importance when the activity is very high, as is the case with radioisotope therapies. Individualized therapy plans, created based on images of a given patient, allow for the optimization of therapy and the minimization of toxic effects [3][4][5][6][7].
Both nuclear medicine and external beam radiotherapy (EBRT) use ionizing radiation to treat malignant tissue. EBRT requires advanced equipment that shapes the external beam to conform to the tumor, and nuclear medicine uses radiopharmaceuticals that are introduced directly into the body. Both treatment techniques should follow the guidelines contained in COUNCIL DIRECTIVE 2013/5/EURATOM from 5 December 2013, concerning the safety of patients diagnosed and treated with ionizing radiation [8]. In Article 56 of the Directive, the following is written: “For all medical exposure of patients for radiotherapeutic purposes, exposures of target volumes shall be individually planned, and their delivery appropriately verified taking into account that doses to non-target volumes and tissues shall be as low as reasonably achievable and consistent with the intended radiotherapeutic purpose of the exposure.” This implies the necessity to personalize the treatment, i.e., the selection of the suitable pharmaceutical, in the right dosage and time. Individual EBRT planning is a common practice that has been developed and used for many years. Teams of physicists involved in treatment planning and clinical dosimetry for each and every patient are the standard in radiotherapy centers. Radiation treatment planning is performed with the use of advanced computer programs using computed tomography (CT), magnetic resonance (MR), or positron emission tomography (PET) images. Modern planning methods include the three-dimensional (3D) technique, which allows for the spatial shaping of radiation beams and the protection of critical organs [9][10].
The situation in nuclear medicine is completely different. Few physicists work in nuclear medicine departments, and radioisotope therapies are usually performed according to standard clinical procedures. Individual calculations of radiopharmaceutical doses for patients are not routinely performed in most nuclear medicine facilities across the world. Nuclear medicine specialists most often use standard activities of radiopharmaceuticals during therapy, considering the patient’s weight or body surface area.
In some cases, administration of standard radiopharmaceutical activities does not provide a sufficiently high dose per tumor to destroy it. On the other hand, giving too much activity could have harmful effects on critical organs. A small fraction of patients receives optimal activity, while the vast majority receive lower doses. This conservative approach provides “radiation safety” to healthy tissues, but also delivers a lower dose than indicated to the neoplastic tissue, resulting in a low response rate and a higher rate of disease relapse. Individualized treatment planning would provide higher absorbed doses to most patients without risking toxicity. “Personalized dosimetry is a must for appropriate molecular radiotherapy”—this is the title of the article by Stabin (one of the pioneers of internal dosimetry) et al. published in 2019 in the Medical Physics journal [11]. 

2. Radionuclides for Therapies

Due to the intensive development of pharmacology, the number of new radiopharmaceuticals that can be used in therapy is increasing every year. A particular advantage of radioisotope therapies is that they can be used in situations where all other forms of treatment have failed. Most radionuclides used in therapy emit β− particles, and rarely α particles, which are highly potent. Table 1 contains information on the radionuclides used in radioisotope therapies. Table 2, on the contrary, presents the radionuclides currently being tested, which provides the evidence of the intensive development of this method of treatment.
Table 1. Radionuclides used in particular types of radioisotope therapies.
Radionuclide Basic Radiation
Type for
Therapy		 Chemical and Dosage Form Indications Administration Route References
Iodine 131I β− Sodium iodide Thyroid carcinoma Oral  
Hyperthyroidism [12][13]
Iodine 131I β−   Pheochromocytoma Intravenous  
Iobenguane Paraganglioma [14][15][16][17]
  Neuroblastoma
Carcinoid		  
Iodine 131I β− Apamistamab Leukemia Intravenous [18]
Iodine 131I β− Tositumomab non-Hodgkin’s lymphoma Intravenous [19][20]
Iodine 131I β− Lipiodol HCC, liver metastasis Intra-arterial
infusion		 [21][22]
Samarium 153Sm β− Lexidronam Painful skeletal metastases Intravenous [23]
Strontium 89Sr β− Strontium chloride Painful skeletal metastases Intravenous [24]
Yttrium 90Y β− Ibritumomabtiuxetan non-Hodgkin’s lymphoma Intravenous [25]
Yttrium 90Y
Therasphere		 β− 90Y glass spheres Unresectable HCC
Liver metastasis		 Intra-arterial
infusion		 [26]
Yttrium 90Y
SIR-Spheres		 β− 90Y resin spheres Unresectable HCC
Liver metastasis		 Intra-arterial
infusion		 [27]
Lutetium 177Lu or
Yttrium 90Y		 β− [177Lu]Lu-DOTATATE
[90Y]Y or [177Lu]Lu-DOTATOC		 Unresectable or metastasized NETs Intravenous [28][29]
Lutetium 177Lu or Actinium225Ac β−
α		 [177Lu]Lu-PSMA Prostate cancer Intravenous  
[225Ac]Ac-PSMA (mCRPC) [30][31]
Phosphorus 32P
Yttrium 90Y
Rhenium 186Re		 β− Colloids Radiosynovectomy Intra-articular
injection		 [32]
Radium 223Ra A Radium dichloride Painful skeletal metastases Intravenous [33][34]
HCC: hepatocellular carcinoma; SSTR2: Somatostatin receptor type 2; PSMA: prostate-specific membrane antigen; NET: neuroendocrine tumor; mCRPC: metastatic castration-resistant prostate cancer.
Table 2. Radionuclides currently introduced into radioisotope therapies, at the stage of research.
Radionuclide Basic Radiation
Type for Therapy		 Indications References
Yttrium 90Y β− Breast cancer [35]
Lutetium 177Lu β− Pancreatic cancer [36][37]
Iodine 131I β− Neuroblastoma Central Nervous System/Leptomeningeal Metastases [38]
Phosphorus 32P β− Pancreatic cancer [39]
Copper 67Cu β− Radioimmunotherapy [40]
Holmium 166Ho β− HCC, liver metastasis [29]
Indium 111In Auger e− GEP-NETs, lung and bladder cancer [41][42][43]
Tin 117mSn Internal conversion e− Painful skeletal metastases [44]
Bismuth 213Bi α Glioblastoma, prostate and bladder cancer [45][46][47]
Astatine 211At A Lung cancer, glioblastoma, radioimmunotherapy [48][49][50][51]
GEP-NET: gastroenteropancreatic neuroendocrine tumor; EC: electron capture.

3. Trends in Personalized Internal Dosimetry

Most of the listed dosimetric problems should be solved within the next few years, and intensive work is currently being undertaken on simplifying the internal dosimetry techniques.
The first simplification concerns the number of necessary scans performed on one patient. The question arises if performing multiple patient acquisitions is necessary and how many of them should be carried out for individual dosimetric calculations. Freedman et al. [52] propose to decrease the series of four standard acquisitions to two post-treatment scans for PRRT with [177Lu]Lu-DOTATATE. However, the authors emphasize the need for further research, as they are concerned that the methods of estimating absorbed doses based on only two scans would be even more user-dependent and require careful analysis of the volumes of interest (VOIs) in images. In a number of papers, published both many years ago and recently [53][54][55][56][57][58][59][60][61][62][63], the authors propose to limit the number of imaging tests performed for dosimetric purposes to one single SPECT/CT acquisition. It is under debate if such simplified dosimetry, based on one measurement, could work properly at all. From a mathematical point of view, there is a lack of measured data to estimate the dose absorbed in a patient’s tissue. However, missing data can be filled with empiric data on the biokinetics of used radiopharmaceuticals. The single time-point dosimetry method requires knowledge about population averages for tracer kinetic parameters. If the biokinetics of the radiopharmaceutical in the analyzed organ and the shape of the TAC have been previously determined based on studies of a given patient population, only one quantitative measurement of the activity at the time corresponding to approximately 1.5 Teff is sufficient (where Teff is the effective elimination half-life of the radiopharmaceutical from the organ) [56][59]. Accuracy analysis of the absorbed dose estimation showed that, for the vast majority of patients, measurement errors were less than 10% [64]. The solution to underestimated or overestimated measurement results could be the creation of databases on the biokinetics of the radiopharmaceutical used in the population. Therefore, in addition to using results of clinical dosimetry measurements to optimize the treatment of individual patients, the obtained data on the biodistribution of used radiopharmaceuticals should also be used to build pharmacokinetic databases on the biokinetics of various radiopharmaceuticals. This population biodistribution should soon become an integral part of programs for simplified, individual internal dosimetry.
The second simplification aims to overcome the difficulties of accurately segmenting organs in SPECT images. Since they have significantly limited resolution, the VOI containing all the accumulated activity is difficult to outline. Moreover, since it is generally larger than the organ itself, the determination of the VOI based on CT images cannot be used because it would not contain all the activity accumulated in the organ. Based on the assumption that the activity in the critical organ is relatively evenly distributed, it has been proposed to evaluate the cumulative dose in the organ based on a “small” VOI placed inside the organ itself [65][66][67]. Since the positioning of this VOI can be difficult and cause differences in dose assessment, an automatic segmentation method has been proposed that eliminates these difficulties [68].
Computer scientists and physicists are developing more and more universal and accessible software for internal dosimetry [69][70][71][72][73].
Due to the rapid development of radiopharmacy, new radiopharmaceutical surrogates can be expected for therapeutic radiopharmaceuticals, which cannot be imaged with the gamma camera [74][75][76]. Radiation dosimetry assessment is often initiated with measuring biodistribution of new radiopharmaceuticals in small animals. To study the biological distribution of radiopharmaceuticals in the human body, it is necessary to find the biological distribution in the rodent body and then the results can be generalized to humans. Preclinical dosimetry studies using small animals are an indispensable step in the pathway from in vitro experiments to clinical implementation of new radioisotope therapies. A lot of studies have shown the practicality of using animal distribution as a model for estimating the absorbed dose in humans [77][78][79][80][81].
Due to the growing awareness of the importance of dosimetry, the Internal Atomic Energy Agency conducts training in that field for doctors and medical physicists. For several years, The European School of Multimodality Imaging and Therapy (ESMIT) has been operating within EANM, the aim of which is to educate specialists at three educational levels, both online and in-person [82][83]. The Dosimetry Project Group, operating within ESMIT, organizes advanced courses for the practical application of clinical dosimetry in radioisotope therapy. The courses enable direct contact with dosimetry experts, exchange of experiences, and cooperation of clinicians, implementing individual internal dosimetry in nuclear medicine facilities around the world. These activities are also related to the existing need for standardization and harmonization of internal clinical dosimetry tools.

This entry is adapted from the peer-reviewed paper 10.3390/cancers14143418

References

  1. Ballal, S.; Yadav, M.; Kramer, V.; Moon, E.; Roesch, F.; Tripathi, M.; Mallick, S.; ArunRaj, S.T.; Bal, C. A theranostic approach of Ga-DOTA.SA.FAPi PET/CT-guided Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: New frontier in targeted radionuclide therapy. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 942–944.
  2. Herrmann, K.; Larson, S.; Weber, W. Theranostic Concepts: More Than Just a Fashion Trend—Introduction and Overview. J. Nucl. Med. 2017, 58, 1S–2S.
  3. Strigari, L.; Konijnenberg, M.; Chiesa, C.; Bardies, M.; Du, Y.; Gleisner, K.S.; Lassmann, M.; Flux, G. The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. Eur. J. Nucl. Med. Mol. Imaging 2014, 41, 1976–1988.
  4. Binnebeek, S.; Baete, K.; Vanbilloen, B.; Terwinghe, C.; Koole, M.; Mottaghy, F.; Clement, P.M.; Mortelmans, L.; Haustermans, K.; Van Cutsem, E.; et al. Individualized dosimetry-based activity reduction of 90Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy. Eur. J. Nucl. Med. Mol. Imaging 2014, 41, 1141–1157.
  5. Ezziddin, S.; Reichmann, K.; Yong-Hing, C.; Damm, M.; Risse, J.; Ahmadzadehfar, H.; Logvinski, T.; Guhlke, S.; Biersack, H.J.; Sabet, A. Early prediction of tumour response to PRRT. Nukl. Nucl. Med. 2013, 52, 170–177.
  6. Sundlov, A.; SjogreenGleisner, K.; Svensson, J.; Ljungberg, M.; Olsson, T.; Bernhardt, P.; Tennvall, J. Individualised 177Lu-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry. Eur. J. Nucl. Med. Mol. Imaging. 2017, 44, 1480–1489.
  7. Barone, R.; Borson-Chazot, F.; Valkema, R.; Walrand, S.; Chauvin, F.; Gogou, L.; Kvols, L.K.; Krenning, E.P.; Jamar, F.; Pauwels, S. Patient-Specific Dosimetry in Predicting Renal Toxicity with 90Y-DOTATOC: Relevance of Kidney Volume and Dose Rate in Finding a Dose–Effect Relationship. J. Nucl. Med. 2005, 46 (Suppl. 1), 99S–106S.
  8. Konijnenberg, M.; Herrmann, K.; Kobe, C.; Verburg, F.; Hindorf, C.; Hustinx, R.; Lassmann, M. EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 67–72.
  9. Chandra, R.; Keane, F.; Voncken, F.; Thomas, C. Contemporary radiotherapy: Present and future. Lancet 2021, 06, 171–184.
  10. Thompson, M.; Poortmans, P.; Chalmers, A.; Faivre-Finn, C.; Hall, E.; Huddart, R.; Lievens, Y.; Sebag-Montefiore, D.; Coles, C.E. Practice-changing radiation therapy trials for the treatment of cancer: Where are we 150 years after the birth of Marie Curie? Br. J. Cancer 2018, 119, 389–407.
  11. Stabin, M.G.; Madsen, M.T.; Zaidi, H. Personalized dosimetry is a must for appropriate molecular radiotherapy. Med. Phys. 2019, 09, 4713–4716.
  12. Maxon, H.R.; Englaro, E.; Thomas, S.; Hertzberg, V.; Hinnefeld, J.; Chen, L.; Smith, H.; Cummings, D.; Aden, M.D. Radioiodine-131 therapy for well-differentiated thyroid cancer-A quantitative radiation dosimetric approach: Outcome and validation in 85 patients. J. Nucl. Med. 1992, 33, 1132–1136.
  13. Benua, R.; Cicale, N.; Sonenberg, M.; Rawson, R. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am. J. Roentgenol. Radium Ther. Nucl. Med. 1962, 87, 171–182.
  14. Fitzgerald, P.; Goldsby, R.; Huberty, J.; Price, D.; Hawkins, R.; Veatch, J.; Dela Cruz, F.; Jahan, T.M.; Linker, C.A.; Damon, L.; et al. Malignant Pheochromocytomas and Paragangliomas: A Phase II Study of Therapy with High-Dose 131I-Metaiodobenzylguanidine (131I- MIBG). Ann. N. Y. Acad. Sci. 2006, 1073, 465–490.
  15. Noto, R.; Pryma, D.; Jensen, J.; Lin, T.; Stambler, N.; Strack, T.; Wong, V.; Goldsmith, S.J. Phase 1 Study of High-Specific-Activity I-131 MIBG for Metastatic and/or Recurrent Pheochromocytoma or Paraganglioma. J. Clin. Endocrinol. Metab. 2017, 3, 213–220.
  16. George, S.; Falzone, N.; Chittenden, S.; Kirk, S.; Lancaster, D.; Vaidya, S.; Mandeville, H.; Saran, F.; Pearson, A.D.; Du, Y.; et al. Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastoma. Nucl. Med. Commun. 2016, 37, 466–472.
  17. Coleman, R.; Stubbs, J.; Barrett, J.; de la Guardia, M.; LaFrance, N.; Babich, J. Radiation Dosimetry, Pharmacokinetics, and Safety of Ultratrace (TM) Iobenguane I-131 in Patients with Malignant Pheochromocytoma/Paraganglioma or Metastatic Carcinoid. Cancer Biother. Radiopharm. 2009, 24, 469–475.
  18. Tomlinson, B.; Reddy, V.; Berger, M.; Spross, J.; Lichtenstein, R.; Gyurkocza, B. Rapid reduction of peripheral blasts in older patients with refractory acute myeloid leukemia (AML) using reinduction with single agent anti-CD45 targeted iodine ( 131 I) apamistamab radioim- munotherapy in the phase III SIERRA trial. J. Clin. Oncol. 2019, 37, 7048.
  19. Vose, J.; Wahl, R.; Saleh, M.; Rohatiner, A.; Knox, S.; Radford, J.; Zelenetz, A.D.; Tidmarsh, G.F.; Stagg, R.J.; Kaminski, M.S. Multicenter Phase II Study of Iodine-131 Tositumomab for Chemotherapy- Relapsed/Refractory Low-Grade and Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2000, 18, 1316–1323.
  20. Horning, S.; Younes, A.; Jain, V.; Kroll, S.; Lucas, J.; Podoloff, D.; Goris, M. Efficacy and Safety of Tositumomab and Iodine-131 Tositumomab (Bexxar) in B-Cell Lymphoma, Progressive After Rituximab. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2005, 23, 712–719.
  21. Yoo, H.S.; Park, C.; Lee, J.; Kim, K.; Yoon, C.; Suh, J.; Park, C.Y.; Kim, B.S.; Choi, H.J.; Lee, K.S.; et al. Small hepatocellular carcinoma: High dose internal radiation therapy with superselective intra-arterial injection of I-131-labeled Lipiodol. Cancer Chemother. Pharmacol. 1994, 33, S128–S133.
  22. Raoul, J.; Guyader, D.; Bretagne, J.; Duvauferrier, R.; Bourguet, P.; Bekhechi, D.; Deugnier, Y.M.; Gosselin, M. Randomized Controlled Trial for Hepatocellular Carcinoma with Portal Vein Thrombosis: Intra-arterial Iodine131Iodized Oil Versus Medical Support. J. Nucl. Med. 1994, 35, 1782–1787.
  23. Eary, J.; Collins, C.; Stabin, M.; Vernon, C.; Petersdorf, S.; Baker, M.; Hartnett, S.; Ferency, S.; Addison, S.J.; Appelbaum, F.; et al. Samarium Sm-EDTMP biodistribution and dosimetry estimation. J. Nucl. Med. 1993, 34, 1031–1036.
  24. Robinson, R.; Preston, D.; Schiefelbein, M.; Baxter, K. Strontium 89 therapy for the palliation of pain due to osseous metastases. JAMA J. Am. Med. Assoc. 1995, 274, 420–424.
  25. Witzig, T.; Flinn, I.; Gordon, L.; Emmanouilides, C.; Czuczman, M.; Saleh, M.; Cripe, L.; Wiseman, G.; Olejnik, T.; Multani, P.S.; et al. Treatment With IbritumomabTiuxetanRadioimmunotherapy in Patients With Rituximab-Refractory Follicular Non-Hodgkin’s Lymphoma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2002, 20, 3262–3269.
  26. Salem, R.; Lewandowski, R.; Roberts, C.; Goin, J.; Thurston, K.; Abouljoud, M.; Courtney, A. Use of Yttrium-90 Glass Microspheres (TheraSphere) for the Treatment of Unresectable Hepatocellular Carcinoma in Patients with Portal Vein Thrombosis. J. Vasc. Interv. Radiol. JVIR 2004, 15, 335–345.
  27. Lau, W.Y.; Ho, S.; Leung, T.W.T.; Chan, M.; Ho, R.; Johnson, P.; Li, A.K. Selective internal radiation therapy for nonresectable hepatocellular carcinoma with intraarterial infusion of 90yttrium microspheres. Int. J. Radiat. Oncol. Biol. Phys. 1998, 40, 583–592.
  28. Strosberg, J.; El-Haddad, G.; Wolin, E.; Hendifar, A.; Yao, J.; Chasen, B.; Mittra, E.; Kunz, P.L.; Kulke, M.H.; Jacene, H.; et al. Phase 3 Trial of 177 Lu-Dotatate for Midgut Neuroendocrine Tumors. N. Engl. J. Med. 2017, 376, 125–135.
  29. Otte, A.; Herrmann, R.; Heppeler, A.; Behe, M.; Jermann, E.; Powell, P.; Maecke, H.; Muller, J. Yttrium-90 DOTATOC: First clinical results. Eur. J. Nucl. Med. 1999, 26, 1439–1447.
  30. Sartor, O.; Bono, J.; Chi, K.; Fizazi, K.; Herrmann, K.; Rahbar, K.; Tagawa, S.T.; Nordquist, L.T.; Vaishampayan, N.; El-Haddad, G.; et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N. Engl. J. Med. 2021, 385, 1091–1103.
  31. Feuerecker, B.; Tauber, R.; Knorr, K.; Heck, M.; Beheshti, A.; Seidl, C.; Bruchertseifer, F.; Pickhard, A.; Gafita, A.; Kratochwil, C.; et al. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA. Eur. Urol. 2020, 79, 343–350.
  32. Liepe, K.; Zaknun, J.; Padhy, A.; Barrenechea, E.; Soroa, V.; Shrikant, S.; Asavatanabodee, P.; Jeong, M.J.; Dondi, M. Radiosynovectomy using yttrium-90, phosphorus-32 or rhenium- 188 radiocolloids versus corticoid instillation for rheumatoid arthritis of the knee. Ann. Nucl. Med. 2011, 25, 317–323.
  33. Nilsson, S.; Strang, P.; Aksnes, A.K.; Franzèn, L.; Olivier, P.; Pecking, A.; Staffurth, J.; Vasanthan, S.; Andersson, C.; Bruland, Ø.S. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur. J. Cancer 2012, 48, 678–686.
  34. Parker, C.; Coleman, R.; Sartor, O.; Vogelzang, N.; Bottomley, D.; Heinrich, D.; Helle, S.I.; O’Sullivan, J.M.; Fosså, S.D.; Chodacki, A.; et al. Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. Eur. Urol. 2018, 73, 427–435.
  35. Lindner, T.; Loktev, A.; Altmann, A.; Giesel, F.; Kratochwil, C.; Debus, J.; Jäger, D.; Mier, W.; Haberkorn, U. Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein. J. Nucl. Med. 2018, 59, 1415–1422.
  36. Baum, R.P.; Singh, A.; Schuchardt, C.; Kulkarni, H.; Klette, I.; Wiessalla, S.; Osterkamp, F.; Reineke, U.; Smerling, C. 177Lu-3BP-227 for Neurotensin Receptor 1-Targeted Therapy of Metastatic Pancreatic Adenocarcinoma: First Clinical Results. J. Nucl. Med. 2018, 59, 809–814.
  37. 131I-Omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases. Available online: https://clinicaltrials.gov/ct2/show/NCT03275402 (accessed on 30 December 2021).
  38. Bhutani, M.; Cazacu, I.; Chavez, A.; Singh, B.; Wong, F.; Erwin, W.; Tamm, E.P.; Mathew, G.G.; Le, D.B.; Koay, E.J.; et al. Novel EUS-guided brachytherapy treatment of pancreatic cancer with phosphorus-32 microparticles: First United States experience. VideoGIE 2019, 4, 223–225.
  39. DeNardo, S.; DeNardo, G.; Kukis, D.; Shen, S.; Kroger, L.; DeNardo, D.; Goldstein, D.S.; Mirick, G.R.; Salako, Q.; Mausner, L.F.; et al. Cu-2IT-BAT-Lym-1 Pharmacokinetics, Radiation Dosimetry, Toxicity and Tumor Regression in Patients with Lymphoma. J. Nucl. Med. 1999, 40, 302–310.
  40. Smits, M.; Nijsen, J.; Bosch, M.; Lam, M.; Vente, M.; Mali, W.; van Het Schip, A.D.; Zonnenberg, B.A. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): A phase 1, dose-escalation study. Lancet Oncol. 2012, 13, 1025–1034.
  41. Rosenkranz, A.; Slastnikova, T.; Karmakova, T.; Vorontsova, M.; Morozova, N.; Petriev, V.; Abrosimov, A.S.; Khramtsov, Y.V.; Lupanova, T.N.; Ulasov, A.V.; et al. Antitumor Activity of Auger Electron Emitter 111In Delivered by Modular Nanotransporter for Treatment of Bladder Cancer With EGFR Overexpression. Front. Pharmacol. 2018, 9, 1331.
  42. Delpassand, E.; Sims-Mourtada, J.; Saso, H.; Azhdarinia, A.; Ashoori, F.; Torabi, F.; Espenan, G.; Moore, W.H.; Woltering, E.; Anthony, L. Safety and Efficacy of Radionuclide Therapy with High-Activity In-111 Pentetreotide in Patients with Progressive Neuroendocrine Tumors. Cancer Biother. Radiopharm. 2008, 23, 292–300.
  43. Divgi, C.; Welt, S.; Kris, M.; Real, F.X.; Yeh, S.; Gralla, R.; Merchant, B.; Schweighart, S.; Unger, M.; Larson, S.M.; et al. Phase I and Imaging Trial of Indium 111-Labeled Anti-Epidermal Growth Factor Receptor Monoclonal Antibody 225 in Patients With Squamous Cell Lung Carcinoma. J. Natl. Cancer Inst. 1991, 83, 97–104.
  44. Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients WITH Prostate Cancer That Has Spread to Bones. Available online: https://clinicaltrials.gov/ct2/show/NCT04616547 (accessed on 30 December 2021).
  45. Kratochwil, C.; Schmidt, K.; Afshar-Oromieh, A.; Bruchertseifer, F.; Rathke, H.; Morgenstern, A.; Haberkorn, U.; Giesel, F.L. Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617. Eur. J. Nucl. Med. Mol. Imaging 2018, 45, 31–37.
  46. Krolicki, L.; Bruchertseifer, F.; Kunikowska, J.; Koziara, H.; Królicki, B.; Jakuciński, M.; Pawlak, D.; Apostolidis, C.; Mirzadeh, S.; Rola, R.; et al. Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with 213Bi-substance P analogue. Eur. J. Nucl. Med. Mol. Imaging 2018, 45, 1636–1644.
  47. Autenrieth, M.; Seidl, C.; Bruchertseifer, F.; Horn, T.; Kurtz, F.; Feuerecker, B.; D’Alessandria, C.; Pfob, C.; Nekolla, S.; Apostolidis, C.; et al. Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: A pilot study. Eur. J. Nucl. Med. Mol. Imaging 2018, 45, 1364–1371.
  48. Kaneda-Nakashima, K.; Zhang, Z.; Manabe, Y.; Shimoyama, A.; Kabayama, K.; Watabe, T.; Kanai, Y.; Ooe, K.; Toyoshima, A.; Shirakami, Y.; et al. α-Emitting cancer therapy using 211 At-AAMT targeting LAT1. Cancer Sci. 2021, 112, 1132–1140.
  49. Li, H.; Morokoshi, Y.; Kodaira, S.; Kusumoto, T.; Minegishi, K.; Kanda, H.; Nagatsu, K.; Hasegawa, S. Utility of 211 At-Trastuzumab for the Treatment of Metastatic Gastric Cancer in the Liver: Evaluation of a Preclinical-Radioimmunotherapy Approach in a Clinically Relevant Mouse Model. J. Nucl. Med. 2021, 62, 1468–1474.
  50. Zalutsky, M.; Reardon, D.; Akabani, G.; Coleman, R.; Friedman, A.; Friedman, H.S.; McLendon, R.E.; Wong, T.Z.; Bigner, D.D. Clinical Experience with -Particle Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6. J. Nucl. Med. 2008, 49, 30–38.
  51. Andersson, H.; Cederkrantz, E.; Back, T.; Divgi, C.; Elgqvist, J.; Himmelman, J.; Horvath, G.; Jacobsson, L.; Jensen, H.; Lindegren, S.; et al. Intraperitoneal -Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab’)2–A Phase I Study. J. Nucl. Med. 2009, 50, 1153–1160.
  52. Freedman, N.; Sandström, M.; Kuten, J.; Shtraus, N.; Ospovat, I.; Schlocker, A.; Even-Sapir, E. Personalized radiation dosimetry for PRRT—how many scans are really required? EJNMMI Phys. 2020, 7, 26.
  53. Amato, E.; Campennı, A.; Ruggeri, R.; Auditore, L.; Baldari, S. Comment on: “Technical note: Single time point dose estimate for exponential clearance” . Med. Phys. 2019, 46, 2776–2779.
  54. Hanscheid, H.; Lassmann, M. Will SPECT/CT Cameras Soon Be Able to Display Absorbed Doses? Dosimetry from Single-Activity- Concentration Measurements. J. Nucl. Med. 2020, 61, 1028–1029.
  55. Hou, X.; Brosch-Lenz, J.; Uribe, C.; Desy, A.; Boening, G.; Beauregard, J.M.; Celler, A.; Rahmim, A. Feasibility of Single-Time-Point Dosimetry for Radiopharmaceutical Therapies. J. Nucl. Med. 2020, 62, 1006–1011.
  56. Jackson, P.; Hofman, M.; Hicks, R.; Scalzo, M.; Violet, J. Radiation Dosimetry in 177 Lu-PSMA-617 Therapy Using a Single Post-treatment SPECT/CT: A Novel Methodology to Generate Time and Tissue-specific Dose Factors. J. Nucl. Med. 2019, 61, 1030–1036.
  57. Bockisch, A.; Jamitzky, T.; Derwanz, R.; Biersack, H.J. Optimized dose planning of radioiodine therapy of benign thyroidal diseases. J. Nucl. Med. 1993, 34, 1632–1638.
  58. Hanscheid, H.; Lassmann, M.; Reiners, C. Dosimetry prior to I-131-therapy of benign thyroid disease. Z. Med. 2011, 21, 250–257.
  59. Hanscheid, H.; Lapa, C.; Buck, A.; Lassmann, M.; Werner, R. Dose Mapping after Endoradiotherapy with 177 Lu-DOTATATE/-TOC by One Single Measurement after Four Days. J. Nucl. Med. 2017, 59, 75–81.
  60. Madsen, M.; Menda, Y.; O’Dorisio, T.; O’Dorisio, M.S. Technical Note: Single time point dose estimate for exponential clearance. Med. Phys. 2018, 45, 2318–2324.
  61. Esquinas, P.; Shinto, A.; Kamaleshwaran, K.; Joseph, J.; Celler, A. Biodistribution, pharmacokinetics, and organ-level dosimetry for 188Re-AHDD- Lipiodol radioembolization based on quantitative post-treatment SPECT/CT scans. EJNMMI Phys. 2018, 5, 30.
  62. Chicheportiche, A.; Ben-Haim, S.; Grozinsky-Glasberg, S.; Oleinikov, K.; Meirovitz, A.; Gross, D.; Godefroy, J. Dosimetry after peptide receptor radionuclide therapy: Impact of reduced number of post-treatment studies on absorbed dose calculation and on patient management. EJNMMI Phys. 2020, 7, 5.
  63. Zhao, W.; Esquinas, P.; Frezza, A.; Hou, X.; Beauregard, J.M.; Celler, A. Accuracy of kidney dosimetry performed using simplified time activity curve modelling methods: A 177Lu-DOTATATE patient study. Phys. Med. Biol. 2019, 64, 175006.
  64. Del Prete, M.; Arsenault, F.; Saighi, N.; Zhao, W.; Buteau, F.A.; Celler, A.; Beauregard, J.M. Accuracy and reproducibility of simplified QSPECT dosimetry for personalized 177Lu-octreotate PRRT. EJNMMI Phys. 2018, 5, 25.
  65. Sandstrom, M.; Garske-Roman, U.; Granberg, D.; Johansson, S.; Widstom, C.; Eriksson, B.; Sundin, A.; Lundqvist, H.; Lubberink, M. Individualized Dosimetry of Kidney and Bone Marrow in Patients Undergoing Lu-177-DOTA-Octreotate Treatment. J. Nucl. Med. 2012, 54, 33–41.
  66. Sandstrom, M.; Ilan, E.; Karlberg, A.; Johansson, S.; Freedman, N.; Garske- Romann, U. Method dependence, observer variability and kidney volumes in radiation dosimetry of (177)Lu-DOTATATE therapy in patients with neuroendocrine tumours. EJNMMI Phys. 2015, 2, 24.
  67. Heikkonen, J.; Maenpaa, H.; Hippelainen, E.; Reijonen, V.; Tenhunen, M. Effect of calculation method on kidney dosimetry in 177 Lu-octreotate treatment. Acta Oncol. 2016, 55, 1069–1076.
  68. Hou, X.; Zhao, W.; Beauregard, J.M.; Celler, A. Personalized kidney dosimetry in 177Lu-octreotate treatment of neuroendocrine tumours: A comparison of kidney dosimetry estimates based on a whole organ and small volume segmentations. Phys. Med. Biol. 2019, 64, 175004.
  69. Santoro, L.; Pitalot, L.; Trauchessec, D.; Mora Ramirez, E.; Kotzki, P.O.; Bardies, M.; Deshayes, E. Clinical implementation of PLANET®Dose for dosimetric assessment after Lu-DOTA-TATE: Comparison with Dosimetry Toolkit® and OLINDA/EXM® V1.0. EJNMMI Res. 2021, 11, 1.
  70. Li, T.; Zhu, L.; Lu, Z.; Song, N.; Lin, K.H.; Mok, G. BIGDOSE: Software for 3D personalized targeted radionuclide therapy dosimetry. Quant. Imaging Med. Surg. 2020, 10, 160–170.
  71. De VriesHuizing, D.; Peters, S.; Versleijen, M.; Martens, E.; Verheij, M.; Sinaasappel, M.; Stokkel, M.P.M.; de Wit-van der Veen, B.J. A head-to-head comparison between two commercial software packages for hybrid dosimetry after peptide receptor radionuclide therapy. EJNMMI Phys. 2020, 7, 36.
  72. Capala, J.; Graves, S.; Scott, A.; Sgouros, G.; St James, S.; Zanzonico, P.; Zimmerman, B.E. Dosimetry for Radiopharmaceutical Therapy: Current Practices and Commercial Resources. J. Nucl. Med. 2021, 62, 3–11.
  73. Chauvin, M.; Borys, D.; Botta, F.; Bzowski, P.; Dabin, J.; Denis-Bacelar, A.; Desbrée, A.; Falzone, N.; Lee, B.Q.; Mairani, A.; et al. OpenDose: Open-Access Resource for Nuclear Medicine Dosimetry. J. Nucl. Med. 2020, 61, 1514–1519.
  74. Ballinger, J. Theranostic radiopharmaceuticals: Established agents in current use. Br. J. Radiol. 2018, 91, 20170969.
  75. Sgouros, G.; Bodei, L.; McDevitt, M.; Nedrow, J. Radiopharmaceutical therapy in cancer: Clinical advances and challenges. Nat. Rev. Drug Discov. 2020, 19, 589–608.
  76. Capala, J.; Kunos, C. A New Generation of “Magic Bullets” for Molecular Targeting of Cancer. Clin. Cancer Res. 2020, 11, 377–379.
  77. Cicone, F.; Gnesin, S.; Denoël, T.; Stora, T.; van der Meulen, N.P.; Müller, C.; Vermeulen, C.; Benešová, M.; Köster, U.; Johnston, K.; et al. Internal radiation dosimetry of a 152Tb-labeled antibody in tumor-bearing mice. EJNMMI Res. 2019, 9, 53.
  78. Gupta, A.; Lee, M.S.; Kim, J.H.; Lee, D.S.; Lee, J.S. Preclinical Voxel-Based Dosimetry in Theranostics: A Review. Nucl. Med. Mol. Imaging 2020, 54, 86–97.
  79. Ukon, N.; Zhao, S.; Washiyama, K.; Oriuchi, N.; Tan, C.; Shimoyama, S.; Aoki, M.; Kubo, H.; Takahashi, K.; Ito, H. Human dosimetry of free 211At and meta-astatobenzylguanidine (211At-MABG) estimated using preclinical biodistribution from normal mice. EJNMMI Phys. 2020, 7, 58.
  80. Sahafi-Pour, S.A.; Shirmardi, S.P.; Saeedzadeh, E.; Baradaran, S.; Sadeghi, M. Internal dosimetry studies of 177Lu-BBN-GABA-DOTA, as a cancer therapy agent, in human tissues based on animal data. Appl. Radiat. Isot. 2022, 186, 110273.
  81. Henry, E.C.; Strugari, M.; Mawko, G.; Brewer, K.; Liu, D.; Gordon, A.C.; Bryan, J.N.; Maitz, C.; Abraham, R.; Kappadath, S.C.; et al. Precision dosimetry in yttrium-90 radioembolization through CT imaging of radiopaque microspheres in a rabbit liver model. EJNMMI Phys. 2022, 9, 21.
  82. Flux, G.; Sjogreen Gleisner, K.; Chiesa, C.; Lassmann, M.; Chouin, N.; Gear, J.; Bardiès, M.; Walrand, S.; Bacher, K.; Eberlein, U.; et al. From fixed activities to personalized treatments in radionuclide therapy: Lost in translation? Eur. J. Nucl. Med. Mol. Imaging 2017, 45, 152–154.
  83. The European School of Multimodality Imaging Therapy Website. Available online: https://www.eanm.org/esmit/7 (accessed on 3 January 2022).
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Video Production Service
Feedback